You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company said it intends to use net proceeds from the offering to support development and commercialization for its DetermaVu and Razor assays.
The San Diego-based company plans to use the proceeds from the financing to enhance its Health Nucleus intelligence platform.
The firm will use the net proceeds for research and development, marketing, and general corporate purposes to help commercialize its LX Analyzer technology.
Cambridge, UK-based Sense Biodetection will use the funding to develop a portfolio of instrument-free, point-of-care molecular diagnostic tests.
The company offers products and services for analyzing, interpreting, and reporting clinical next-generation sequencing data with a focus on cancer.
The company has used a portion of the new facility to pay back existing debt to the bank, as well as a final payment designated in the parties' earlier loan agreement.
The firm said that the second tranche is part of the financing provided by Ampersand Capital for the $23.5 million acquisition of Cancer Genetics' biopharma business earlier this year.
Last week's SynBioBeta conference was indicative of the high degree of interest in the synthetic bio space from omics research tool vendors.
Ginkgo plans to strategically partner with leading companies in mature markets to create synthetic biology-based spinouts, something it has already done in ag-bio.
The company was originally founded as a spinoff from Korean genomic services provider Macrogen to offer direct-to-consumer genomic rare disease screening tests.
Following discrimination allegations, NICHD's Constantine Stratakis withdraws from a new position at the Research Institute of the McGill University Health Center, Science reports.
US President Donald Trump has threatened to cut World Health Organization funding over its pandemic response, which would affect its ability to do its work and which he might not be able to do.
The US Securities and Exchange Commission has halted the sales of a handful of stocks over claims made about the coronavirus.
In Nature this week: comparative analyses of single-cell RNA sequencing protocols uncover differences between approaches, and more.